Headlines about Gilead Sciences (NASDAQ:GILD) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gilead Sciences earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 91 out of 100, meaning that recent media coverage is extremely likely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern’s analysis:
- Q2 2017 EPS Estimates for Gilead Sciences, Inc. (NASDAQ:GILD) Increased by Analyst (americanbankingnews.com)
- 5 Ways Gilead Sciences Could Spend Its Cash Hoard (fool.com)
- Low expectations for a company’s potential earnings growth:: Gilead Sciences, Inc. (GILD) – Street Observer (press release) (streetobserver.com)
- 9 Reasons Gilead Will Not Acquire Incyte – Seeking Alpha (seekingalpha.com)
- Gilead Sciences, Inc. (NASDAQ:GILD) Upgraded to Buy at Zacks Investment Research (americanbankingnews.com)
Shares of Gilead Sciences (NASDAQ GILD) traded down 0.38% during trading on Tuesday, reaching $70.88. 767,314 shares of the company’s stock traded hands. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $88.85. The company’s 50-day moving average is $66.03 and its 200 day moving average is $68.95. The company has a market cap of $92.62 billion, a price-to-earnings ratio of 7.49 and a beta of 1.20.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. Equities analysts forecast that Gilead Sciences will post $8.37 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, June 29th. Shareholders of record on Friday, June 16th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.92%. The ex-dividend date was Wednesday, June 14th. Gilead Sciences’s dividend payout ratio is currently 21.99%.
A number of research analysts have commented on GILD shares. Barclays PLC restated a “buy” rating and set a $90.00 price target on shares of Gilead Sciences in a research note on Wednesday, March 22nd. Jefferies Group LLC reiterated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, March 22nd. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $75.07 target price for the company in a report on Tuesday, April 4th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $82.00 target price on shares of Gilead Sciences in a report on Thursday, April 6th. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 11th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, fifteen have assigned a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $80.24.
ILLEGAL ACTIVITY NOTICE: “Gilead Sciences (NASDAQ:GILD) Receives News Impact Rating of 0.11” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://sportsperspectives.com/2017/07/18/somewhat-positive-press-coverage-extremely-likely-to-impact-gilead-sciences-gild-share-price-updated-updated.html.
In other news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares in the company, valued at $7,318,327.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Francis Cogan sold 9,943 shares of Gilead Sciences stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the sale, the director now directly owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. Insiders sold a total of 88,276 shares of company stock worth $6,230,610 in the last quarter. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.